HDAC6 and familial pancreatic carcinoma: Based on prior evidence of efficacy from paclitaxel and HDAC inhibitor combination treatment, the anti-cancer potential of paclitaxel in combination with selective HDAC6 inhibitors was assessed in multiple solid tumor xenograft models, including those of ovarian and pancreatic cancer origins.